Hjem › Urotelial (overgangscelle) karcinom › California › Orange
Kliniske studier for Urotelial (overgangscelle) karcinom i Orange, CA
10 studier for Urotelial (overgangscelle) karcinom søker deltakere på steder i og rundt Orange (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RekruttererFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
RekruttererFase 1/2
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045), Orange
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
RekruttererFase 1/2
- UC Irvine Health, Orange
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekruttererFase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
RekruttererFase 1
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RekruttererFase 3
- UC Irvine Health. Chao Family Comprehensive Cancer Center, Orange
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
RekruttererTidlig fase 1
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RekruttererFase 2
- UC Irvine Health, Orange
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
RekruttererFase 2
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Orange
Urotelial (overgangscelle) karcinom-studier i andre byer
- Nashville, TN23 studier
- New York City, NY22 studier
- Houston, TX19 studier
- Dallas, TX18 studier
- Edison, NJ18 studier
- Los Angeles, CA17 studier
- Queens, NY15 studier
- Chicago, IL14 studier
- Arlington, VA12 studier
- Boston, MA11 studier
- San Antonio, TX11 studier
- Austin, TX10 studier
Andre studier i Orange
- Ikke-småcellet lungekreft25 studier
- Metastatisk kreft20 studier
- Kolorektal kreft16 studier
- Eggstokkreft16 studier
- Pankreaskreft15 studier
- Melanom14 studier
- Leverkreft (hepatocellulært karcinom)14 studier
- Brystkreft14 studier
- Lungekreft14 studier
- Prostatakreft14 studier
- Mavekreft13 studier
- Kreft (alle typer)13 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.